Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$22.40 USD

22.40
1,189,759

-0.15 (-0.67%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $22.41 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?

Horizon Pharma plc (HZNP) is scheduled to report fourth-quarter 2016 results on Feb 27, before the opening bell.

    ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?

    ACADIA Pharmaceuticals Inc. (ACAD) is expected to report fourth-quarter 2016 results on Feb 28.

      TriMas (TRS) to Post Q4 Earnings: What's in the Cards?

      TriMas Corporation (TRS) is scheduled to report fourth-quarter 2014 results on Feb 28, before the opening bell.

        Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?

        Juno Therapeutics Inc. (JUNO) is set to report fourth-quarter 2016 results on Mar 1, after the market closes.

          Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?

          Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.

            Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?

            Endo International plc (ENDP) is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell.

              Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?

              Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.

                Can Penumbra (PEN) Spring a Surprise this Earnings Season?

                Penumbra Inc. (PEN) is slated to release fourth-quarter 2016 results on Feb 28, after market close.

                  Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?

                  Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report fourth-quarter 2016 results on Feb 23.

                    Ionis (IONS) Q4 Earnings: What's in the Cards for the Stock?

                    Ionis Pharmaceuticals, Inc. (IONS) is scheduled to report fourth-quarter 2016 results on Feb 28.

                      Patterson Companies (PDCO) Q3 Earnings: What's in Store?

                      Patterson Companies Inc. (PDCO) is set to report fiscal third-quarter 2017 results on Feb 23, before the opening bell.

                        Arpita Dutt headshot

                        Forget Alexion, Buy these 4 Biotech Stocks Instead

                        We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

                          Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?

                          Ireland-based medical device major Medtronic plc (MDT) is slated to report its third-quarter fiscal 2017 earnings on Feb 21, before the opening bell.

                            Merrimack (MACK): What Awaits the Stock in Q4 Earnings?

                            Merrimack Pharmaceuticals, Inc. (MACK) is scheduled to report fourth-quarter 2016 results in the next week. Last quarter, Merrimack delivered a positive earnings surprise of 23.33%.

                              Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?

                              Radius Health, Inc. (RDUS) is scheduled to report fourth-quarter 2016 financial results on Feb 23.

                                BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?

                                We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23

                                  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                                  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

                                    Arpita Dutt headshot

                                    Forget Gilead, Buy These 5 Biotech Stocks Instead

                                    With Gilead (GILD) providing a not-so-rosy outlook for 2017 as its HCV franchise continues to face challenges, here's a look at 5 biotech stocks that look better-positioned.

                                      ITT Inc. (ITT) Q4 Earnings: What's in Store for the Stock?

                                      ITT Inc. (ITT) is slated to report fourth-quarter 2016 results before the opening bell on Feb 14.

                                        Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?

                                        Allscripts Healthcare Solutions Inc. (MDRX) is scheduled to release fourth-quarter 2016 results on Feb 16.

                                          Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors

                                          Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors

                                            Exelixis (EXEL) Shares March Higher, Can It Continue?

                                            As of late, it has definitely been a great time to be an investor in Exelixis, Inc. (EXEL).

                                              Can Nutrisystem (NTRI) Surprise Investors in Q4 Earnings?

                                              Nutrisystem Inc. (NTRI) is scheduled to release fourth-quarter 2016 results on Feb 27.

                                                Ecolab (ECL): What's in the Cards this Earnings Season?

                                                St. Paul, MN-based Ecolab Inc. (ECL), a leading provider of water, hygiene and energy technologies and services, is expected to report fourth-quarter 2016 results on Feb 21.

                                                  Tirthankar Chakraborty headshot

                                                  Buy 4 Stocks Riding High on Superb Earnings Acceleration

                                                  If the rate of a company's quarter-over-quarter earnings growth increases within a stipulated frame of time, it can be referred to as earnings acceleration.